Tyme Technologies, Inc. , a clinical stage biotechnology company developing cancer therapeutics that are designed to be effective across multiple tumor types, announced that the USPTO has issued patent number 9,549,969 . This substantially expands on issued patent number 8,481,498 in respect to using tyrosine derivatives in combination with agents that may increase oxidative stress to cause tumor cell death.